Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: Systematic review and meta-analysis

BMJ (Online)

Volumn 360, Issue , 2018, Pages

  Baxi, Shrujal ^a,b   Yang, Annie ^a   Gennarelli, Renee L ^a   Khan, Niloufer ^a   Wang, Ziwei ^c   Boyce, Lindsay ^a   Korenstein, Deborah ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; BIOLOGICAL PRODUCT; CARBOPLATIN; CETUXIMAB; EVEROLIMUS; NIVOLUMAB; PEMBROLIZUMAB; PEMETREXED; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTHRALGIA; ARTHRITIS; BACKACHE; COLITIS; DIARRHEA; DRUG TARGETING; FATIGUE; HEPATITIS; HUMAN; HYPOPHYSITIS; HYPOTHYROIDISM; MALIGNANT NEOPLASM; META ANALYSIS (TOPIC); MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; MYALGIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNITY; IMMUNOLOGY; META ANALYSIS; NEOPLASM;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; HUMANS; IMMUNITY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85044071066     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.k793     Document Type: Review

References (45)

1. IMS Institute for Healthcare Informatics. Global Use of Medicines: Outlook through 2017. 2017. http://www.quotidianosanita.it/allegati/allegato1501906.pdf
2. Abdel-Rahman O, ElHalawani H, Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy 2015;7:1213-27. 10.2217/imt.15.87
3. De Velasco G, Je Y, Bossé D, et al. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res 2017;5:312-8. 10.1158/2326-6066.CIR-16-0237
4. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS One 2016;11:e0160221. 10.1371/journal.pone.0160221
5. Abdel-Rahman O, Helbling D, Schmidt J, et al. Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis. Clin Oncol (R Coll Radiol) 2016;28:e127-38. 10.1016/j.clon.2016.06.008
6. Abdel-Rahman O, Fouad M. A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. Immunotherapy 2016;8:665-74. 10.2217/imt-2015-0020
7. Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis 2016;10:183-93. 10.1177/1753465816636557
8. Abdel-Rahman O, ElHalawani H, Fouad M. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Expert Opin Drug Saf 2015;14:1507-18. 10.1517/14740338.2015.1085969
9. Cappelli LC, Shah AA, Bingham CO 3rd. Cancer immunotherapyinduced rheumatic diseases emerge as new clinical entities. RMD Open 2016;2:e000321. 10.1136/rmdopen-2016-000321
10. Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017;76:43-50. 10.1136/annrheumdis-2016-209595
11. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-9.10.7326/0003-4819-151-4-200908180-00135
12. Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. Deduplication of database search results for systematic reviews in EndNote. J Med Libr Assoc 2016;104:240-3. 10.3163/1536-5050.104.3.014
13. Higgins JP, Altman DG, Gøtzsche PC, et al, Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. 10.1136/bmj.d5928
14. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-smallcell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. 10.1016/S0140-6736(15)01281-7
15. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015;16:908-18. 10.1016/S1470-2045(15)00083-2
16. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:1627-39. 10.1056/NEJMoa1507643
17. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:123-35. 10.1056/NEJMoa1504627
18. Motzer RJ, Escudier B, McDermott DF, et al, CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015;373:1803-13. 10.1056/NEJMoa1510665
19. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30. 10.1056/NEJMoa1412082
20. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-84. 10.1016/S1470-2045(15)70076-8
21. Fehrenbacher L, Spira A, Ballinger M, et al, POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-46. 10.1016/S0140-6736(16)00587-0
22. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375:1856-67. 10.1056/NEJMoa1602252
23. Langer CJ, Gadgeel SM, Borghaei H, et al, KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17:1497-508. 10.1016/S1470-2045(16)30498-3
24. Reck M, Rodríguez-Abreu D, Robinson AG, et al, KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375: 1823-33. 10.1056/NEJMoa1606774
25. Bellmunt J, de Wit R, Vaughn DJ, et al, KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017;376:1015-26. 10.1056/NEJMoa1613683
26. Rittmeyer A, Barlesi F, Waterkamp D, et al, OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255-65. 10.1016/S0140-6736(16)32517-X
27. Komaki Y, Komaki F, Yamada A, Micic D, Ido A, Sakuraba A. Meta-analysis of the risk of immune-related adverse events with anticytotoxic T-lymphocyte-associated antigen 4 and antiprogrammed death 1 therapies. Clin Pharmacol Ther 2018;103:318-31. 10.1002/cpt.633
28. Richtel M. Immune System, Unleashed by Cancer Therapies, Can Attack Organs. New York Times [Internet]; 2016. https://www. nytimes.com/2016/12/03/health/immunotherapy-cancer.html
29. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol 2015;33:2092-9. 10.1200/JCO.2014.60.0379
30. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med 2017;376:957-70. 10.1056/NEJMra1505557
31. Cappelli LC, Gutierrez AK, Bingham CO 3rd, Shah AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature. Arthritis Care Res (Hoboken). 2017;69:1751-63. 10.1002/acr.23177
32. Cappelli LC, Shah AA, Bingham CO 3rd. Immune-Related Adverse Effects of Cancer Immunotherapy-Implications for Rheumatology. Rheum Dis Clin North Am 2017;43:65-78. 10.1016/j. rdc.2016.09.007
33. Christ L, Mönch S, Hasmann S, et al. FRI0606 Characteristics and treatment of new onset arthritis after checkpoint inhibitor therapy. Ann Rheum Dis 2017;76(Suppl 2):718.
34. Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer - clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 2018;77:393-8. 10.1136/annrheumdis-2017-212257
35. Anvik T, Holtedahl KA, Mikalsen H. "When patients have cancer, they stop seeing me" - the role of the general practitioner in early follow-up of patients with cancer - a qualitative study. BMC Fam Pract 2006;7:19. 10.1186/1471-2296-7-19
36. Uyl-de Groot CA, Brouwer WBF, de Maeseneer JM, Verweij J. Primary care in cancer control: towards mature cancer care. Lancet Oncol 2015;16:1226-7. 10.1016/S1470-2045(15)00294-6
37. Weber JS, Postow M, Lao CD, Schadendorf D. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. Oncologist 2016;21:1230-40. 10.1634/theoncologist.2016-0055
38. Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med 2016;4:272. 10.21037/atm.2016.07.10
39. Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical trials: a narrative review. Postgrad Med 2011;123:194-204. 10.3810/pgm.2011.09.2475
40. Belkhir R, Burel SL, Lambotte O, et al. OP0004 Rheumatoid arthritis occuring after immune checkpoint inhibitors. Ann Rheum Dis 2017;76(Suppl 2):1747-50. 10.1136/annrheumdis-2017-211216
41. Larkin J, Chmielowski B, Lao CD, et al. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Oncologist 2017;22:709-18. 10.1634/theoncologist.2016-0487
42. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60(Supplement C):210-25. 10.1016/j. ejca.2016.02.024
43. Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015;3:11. 10.1186/s40425-015-0057-1
44. Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 2016;375:1749-55. 10.1056/NEJMoa1609214
45. Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham JJ. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ 2014;349:g6501. 10.1136/bmj.g6501